AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Bacterial Infections: Sulfabenzamide is used to treat various bacterial infections, including urinary tract infections, respiratory tract infections, wound infections, and gastrointestinal infections caused by susceptible bacteria.
Bacteriostatic Action: Sulfabenzamide works by interfering with the synthesis of dihydrofolic acid, a precursor to folate, which is essential for bacterial growth and reproduction. By inhibiting dihydropteroate synthase, an enzyme involved in folate synthesis, sulfabenzamide prevents bacteria from producing essential components for DNA and RNA synthesis, ultimately halting their growth and replication.
Broad Spectrum of Activity: Sulfabenzamide has a broad spectrum of activity against both gram-positive and gram-negative bacteria. It is effective against many common pathogens, including Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae, among others.
Oral Administration: Sulfabenzamide is typically administered orally in the form of tablets or capsules. It is absorbed from the gastrointestinal tract and distributed throughout the body via the bloodstream to reach various tissues and infected sites.
Adverse Effects: Like other sulfonamide antibiotics, sulfabenzamide may cause adverse effects in some individuals. Common side effects may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, or abdominal pain. Allergic reactions, including rash, itching, or hives, are possible but uncommon. Rare but serious adverse effects may include severe skin reactions, blood disorders, or liver and kidney problems.
Dosage and Administration: The dosage of sulfabenzamide depends on the type and severity of the infection, as well as the patient's age, weight, and renal function. It is important to follow the prescribing physician's instructions and complete the full course of treatment as directed, even if symptoms improve before the medication is finished.
Pregnancy and Lactation: The use of sulfabenzamide during pregnancy and lactation should be carefully considered, weighing the potential benefits against the risks to the mother and fetus. Sulfonamide antibiotics may cross the placenta and enter breast milk, potentially affecting the developing fetus or newborn. The decision to use sulfabenzamide should be made in consultation with a healthcare provider.
Bacterial Resistance: As with other antibiotics, the overuse or misuse of sulfabenzamide can contribute to the development of bacterial resistance. Bacteria may develop mechanisms to evade the effects of sulfabenzamide or other antibiotics, leading to treatment failures and the emergence of multidrug-resistant pathogens.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.1 | 0.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0.1 | 0.1 | |
| Allergy to milk products | 0 | 0.1 | 0 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.2 | 0.3 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 0.4 | 0 | 0 |
| Anorexia Nervosa | 0.1 | 0 | 0 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.1 | 2 |
| Asthma | 0 | 0 | |
| Atrial fibrillation | 0.4 | 0.2 | 1 |
| Autism | 0.4 | 0.6 | -0.5 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Bipolar Disorder | 0.2 | 0.2 | |
| Brain Trauma | 0 | 0 | |
| Carcinoma | 0.5 | 0.1 | 4 |
| Celiac Disease | 0.4 | 0.2 | 1 |
| Cerebral Palsy | 0.3 | 0 | 0 |
| Chronic Fatigue Syndrome | 0.6 | 0.5 | 0.2 |
| Chronic Kidney Disease | 0.1 | 0.1 | |
| Chronic Lyme | 0 | 0 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.9 | |
| Chronic Urticaria (Hives) | 0.3 | 0.1 | 2 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.3 | 0.33 |
| Colorectal Cancer | 0.2 | 0.2 | |
| Constipation | 0 | 0 | |
| COVID-19 | 0.4 | 0.4 | 0 |
| Crohn's Disease | 0.3 | 0.2 | 0.5 |
| cystic fibrosis | 0 | 0 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 1.7 | 0.6 | 1.83 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.4 | -0.4 | |
| Endometriosis | 0.4 | 0.4 | |
| Epilepsy | 0.4 | 0.1 | 3 |
| Fibromyalgia | 0.1 | 0 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.1 | 1 |
| gallstone disease (gsd) | 0.1 | 0.1 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.3 | -2 |
| Generalized anxiety disorder | 0 | 0 | |
| Glioblastoma | 0.3 | -0.3 | |
| Graves' disease | 0.1 | 0.1 | |
| Halitosis | 0 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0 | 0.1 | 0 |
| Hidradenitis Suppurativa | 0.4 | 0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0 | 0 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.4 | 0.5 | -0.25 |
| Hypoxia | 0.1 | 0.1 | |
| Inflammatory Bowel Disease | 0.4 | 0.2 | 1 |
| Insomnia | 0.4 | 0 | 0 |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 0 | 0.1 | 0 |
| Liver Cirrhosis | 0.5 | 0.4 | 0.25 |
| Long COVID | 0.4 | 0.2 | 1 |
| ME/CFS with IBS | 0.3 | 0 | 0 |
| ME/CFS without IBS | 0.4 | 0.1 | 3 |
| Metabolic Syndrome | 0.6 | 0.6 | 0 |
| Mood Disorders | 1.8 | 0.6 | 2 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.1 | 0.6 | 0.83 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| Neuropathy (all types) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0 | 0 |
| Obesity | 0.5 | 0.3 | 0.67 |
| obsessive-compulsive disorder | 0.5 | 0 | 0 |
| Osteoarthritis | 0.4 | 0.4 | |
| Osteoporosis | 0 | 0 | 0 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 0.5 | 0.4 | 0.25 |
| Polycystic ovary syndrome | 0.1 | 0.1 | |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| Psoriasis | 0.4 | 0.2 | 1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.1 | 4 |
| Schizophrenia | 0.2 | 0.2 | |
| scoliosis | 0.1 | -0.1 | |
| Sjögren syndrome | 0.4 | 0.1 | 3 |
| Sleep Apnea | 0 | 0 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.1 | 0 | 0 |
| Systemic Lupus Erythematosus | 0.6 | 0.6 | |
| Tourette syndrome | 0 | 0 | |
| Type 1 Diabetes | 0.2 | 0.3 | -0.5 |
| Type 2 Diabetes | 0.6 | 0.5 | 0.2 |
| Ulcerative colitis | 0.4 | 0.2 | 1 |
| Unhealthy Ageing | 0.5 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.